Teprotumumab
Modify Date: 2025-09-11 10:28:24
Teprotumumab structure
|
Common Name | Teprotumumab | ||
|---|---|---|---|---|
| CAS Number | 1036734-93-6 | Molecular Weight | N/A | |
| Density | N/A | Boiling Point | N/A | |
| Molecular Formula | N/A | Melting Point | N/A | |
| MSDS | N/A | Flash Point | N/A | |
Use of TeprotumumabTeprotumumab is an IGF-1 receptor (IGF-1R) blocking human monoclonal antibody. Teprotumumab binds to the ligand binding extracellular α-subunit domain of IGF-1R. Teprotumumab inhibits TSH and IGF-1 action in fibrocytes. Teprotumumab attenuates TSH-dependent IL-6 and IL-8 expression and Akt phosphorylation. Teprotumumab can be used for thyroid-associated ophthalmopathy research[1]. |
| Name | Teprotumumab |
|---|
| Description | Teprotumumab is an IGF-1 receptor (IGF-1R) blocking human monoclonal antibody. Teprotumumab binds to the ligand binding extracellular α-subunit domain of IGF-1R. Teprotumumab inhibits TSH and IGF-1 action in fibrocytes. Teprotumumab attenuates TSH-dependent IL-6 and IL-8 expression and Akt phosphorylation. Teprotumumab can be used for thyroid-associated ophthalmopathy research[1]. |
|---|---|
| Related Catalog | |
| In Vitro | Teprotumumab (0-500 μg/mL, 12 h) attenuates the actions of both IGF-1 and TSH in fibrocytes. IGF-1R and TSHR mRNA abundance is unaffected by Teprotumumab after 24 hours[1]. |
| No Any Chemical & Physical Properties |